Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Darunavir (Prezista®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0907. 2007 Authors' conclusions Darunavir (Prezista®) should be recommended within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in highly pre-treated adults who have failed more than one regimen containing a protease inhibitor (PI), and where resistance profiling suggests it is appropriate.
Use should be in accordance with the British HIV Association (BHIVA) guidance.
Darunavir (Prezista®) is not presently recommended for shared care. Indexing Status Subject indexing assigned by CRD MeSH HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000457 Date abstract record published 08/08/2012 |
